

Georgios Schoretsanitis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4239824/publications.pdf>

Version: 2024-02-01

122
papers

3,180
citations

218677

26
h-index

189892

50
g-index

133
all docs

133
docs citations

133
times ranked

2093
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries. <i>Revista De Psiquiatria Y Salud Mental</i> , 2022, 15, 238-250. | 1.8 | 31 |
| 2 | Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. <i>Revista De Psiquiatria Y Salud Mental</i> , 2022, 15, 117-133. | 1.8 | 2 |
| 3 | Core clinical manifestations of clozapine-related DRESS syndrome: A network analysis. <i>Schizophrenia Research</i> , 2022, 243, 451-453. | 2.0 | 5 |
| 4 | Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. <i>Schizophrenia Bulletin</i> , 2022, 48, 296-306. | 4.3 | 21 |
| 5 | Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2022, 24, 264-274. | 1.9 | 24 |
| 6 | Polycystic ovary syndrome and postpartum depression: A systematic review and meta-analysis of observational studies. <i>Journal of Affective Disorders</i> , 2022, 299, 463-469. | 4.1 | 11 |
| 7 | Esketamine for treatment-resistant depression in adults. <i>The Cochrane Library</i> , 2022, 2022, . | 2.8 | 0 |
| 8 | Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies. <i>British Journal of Psychiatry</i> , 2022, 221, 591-602. | 2.8 | 29 |
| 9 | Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 531-541. | 2.5 | 9 |
| 10 | Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland. <i>Journal of Personalized Medicine</i> , 2022, 12, 441. | 2.5 | 10 |
| 11 | An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 537-540. | 3.2 | 6 |
| 12 | An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86. | 3.3 | 107 |
| 13 | Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 243-249. | 3.1 | 2 |
| 14 | Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 585-587. | 2.4 | 4 |
| 15 | Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. <i>European Neuropsychopharmacology</i> , 2022, 60, 25-37. | 0.7 | 14 |
| 16 | Promoting safer clozapine dosing in the Americas. <i>Revista Brasileira De Psiquiatria</i> , 2022, , . | 1.7 | 2 |
| 17 | Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis. <i>Pharmacopsychiatry</i> , 2022, , . | 3.3 | 0 |
| 18 | Clozapine and the risk of haematological malignancies. <i>Lancet Psychiatry</i> , 2022, 9, 537-538. | 7.4 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2022, 15, 117-133. | 0.3 | 0 |
| 20 | Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. <i>Pharmacopsychiatry</i> , 2022, , . | 3.3 | 0 |
| 21 | The therapeutic reference range for olanzapine revised â€“ how to combine old and new findings. <i>Pharmacopsychiatry</i> , 2022, , . | 3.3 | 0 |
| 22 | Is it Time to Reevaluate the Therapeutic Reference Range for the Antidepressant Drug Venlafaxine?. <i>Pharmacopsychiatry</i> , 2022, , . | 3.3 | 0 |
| 23 | An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine. <i>Annals of General Psychiatry</i> , 2022, 35, e100773. | 3.1 | 11 |
| 24 | Metamizole but not ibuprofen reduces the plasma concentration of sertraline: Implications for the concurrent treatment of pain and depression/anxiety disorders. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1111-1119. | 2.4 | 5 |
| 25 | Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. <i>Pharmacopsychiatry</i> , 2021, 54, 31-35. | 3.3 | 5 |
| 26 | Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 41-48. | 8.8 | 63 |
| 27 | An update on the complex relationship between clozapine and pneumonia. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 145-149. | 3.1 | 30 |
| 28 | Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 79-102. | 2.0 | 23 |
| 29 | Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. <i>Journal of Psychopharmacology</i> , 2021, 35, 273-278. | 4.0 | 13 |
| 30 | European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 140-147. | 1.4 | 19 |
| 31 | The role of cytochrome P450 enzyme genetic variants in cannabis hyperemesis syndromeâ€”A case report. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 82-85. | 2.5 | 4 |
| 32 | The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 353-371. | 1.6 | 16 |
| 33 | Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1437-1443. | 3.2 | 4 |
| 34 | Authorsâ€™ Reply to Suhas et al.: Comment on: â€œElevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivationâ€” <i>Clinical Pharmacokinetics</i> , 2021, 60, 1077-1079. | 3.5 | 0 |
| 35 | Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110228. | 4.8 | 18 |
| 36 | Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review. <i>Journal of Psychopharmacology</i> , 2021, 35, 1062-1073. | 4.0 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1583-1589. | 3.5 | 1 |
| 38 | Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2141-2150. | 2.2 | 4 |
| 39 | Antenatal Antidepressant Prescription Associated With Reduced Fetal Femur Length but Not Estimated Fetal Weight. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 571-578. | 1.4 | 0 |
| 40 | Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 986-996. | 4.3 | 9 |
| 41 | Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation. <i>Clinical Pharmacokinetics</i> , 2021, 60, 329-335. | 3.5 | 20 |
| 42 | Reply to the Comments by Doherty et al.. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 140-141. | 8.8 | 1 |
| 43 | The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. <i>Pharmacopsychiatry</i> , 2020, 53, 65-70. | 3.3 | 2 |
| 44 | Dose and safety concerns of clozapine: Worldwide package inserts need revisions. <i>Schizophrenia Research</i> , 2020, 216, 2-4. | 2.0 | 16 |
| 45 | Excretion of Antipsychotics Into the Amniotic Fluid, Umbilical Cord Blood, and Breast Milk: A Systematic Critical Review and Combined Analysis. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 245-254. | 2.0 | 22 |
| 46 | Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 749-761. | 7.4 | 66 |
| 47 | Prenatal complications and neurodevelopmental outcomes in offspring: interactions and confounders. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 261-263. | 4.5 | 4 |
| 48 | Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. <i>Indian Journal of Psychological Medicine</i> , 2020, 42, 4-10. | 1.5 | 61 |
| 49 | Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215. | 5.5 | 52 |
| 50 | Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 687. | 2.8 | 9 |
| 51 | CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research. <i>Pharmacogenomics</i> , 2020, 21, 1139-1144. | 1.3 | 5 |
| 52 | Changes in Clozapine Bioavailability in a Percutaneous Endoscopic Gastrostomy-Fed Patient With Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 306-308. | 1.4 | 4 |
| 53 | Adding Oral Contraceptives to Clozapine May Require Halving the Clozapine Dose. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 308-310. | 1.4 | 16 |
| 54 | Edentulousness in severely mentally ill patients: A pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene. <i>Schizophrenia Research</i> , 2020, 224, 178-179. | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Is there a future for <i>CYP1A2</i> pharmacogenetics in the optimal dosing of clozapine?. <i>Pharmacogenomics</i> , 2020, 21, 369-373. | 1.3 | 33 |
| 56 | The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxineâ€”A case report. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 354-357. | 2.5 | 3 |
| 57 | Clozapine is strongly associated with the risk of pneumonia and inflammation. <i>Annals of General Psychiatry</i> , 2020, 33, e100183. | 3.1 | 50 |
| 58 | Prolactin changes during electroconvulsive therapy: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2020, 128, 25-32. | 3.1 | 2 |
| 59 | Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 875-883. | 3.1 | 26 |
| 60 | Around 3% of 1,300 Levels Were Elevated during Infections in a Retrospective Review of 131 Beijing Hospital In-Patients with More than 24,000 Days of Clozapine Treatment. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 255-257. | 8.8 | 37 |
| 61 | Using therapeutic drug monitoring to personalize clozapine dosing in Asians. <i>Asia-Pacific Psychiatry</i> , 2020, 12, e12384. | 2.2 | 29 |
| 62 | Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 309-311. | 2.0 | 1 |
| 63 | Pregnancy exposure to venlafaxineâ€”Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. <i>Journal of Affective Disorders</i> , 2020, 266, 578-584. | 4.1 | 10 |
| 64 | Pharmacokinetic interactions between clozapine and sertraline in smokers and nonâ€”smokers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 303-308. | 2.5 | 8 |
| 65 | The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 431-440. | 3.3 | 31 |
| 66 | A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 200-214. | 8.8 | 101 |
| 67 | Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. <i>European Neuropsychopharmacology</i> , 2020, 35, 1-11. | 0.7 | 12 |
| 68 | High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers. <i>Revista Colombiana De PsiquiatrÃa</i> , 2020, 49, 84-95. | 0.3 | 6 |
| 69 | Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, . | 2.2 | 86 |
| 70 | Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2020, 82, . | 2.2 | 15 |
| 71 | Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 41-48. | 2.0 | 4 |
| 72 | Mood Stabilizers: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. , 2020, , 1-24. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Patterns of clozapine pharmacokinetics in patient subgroups with different body mass index. , 2020, 53, . | | 0 |
| 74 | 22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment. Pharmacopsychiatry, 2020, 53, . | 3.3 | 0 |
| 75 | Antidepressants in breast milk; comparative analysis of excretion ratios. Archives of Women's Mental Health, 2019, 22, 383-390. | 2.6 | 22 |
| 76 | A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Review of Clinical Pharmacology, 2019, 12, 603-621. | 3.1 | 69 |
| 77 | Inferior frontal gyrus gray matter volume is associated with aggressive behavior in schizophrenia spectrum disorders. Psychiatry Research - Neuroimaging, 2019, 290, 14-21. | 1.8 | 9 |
| 78 | Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophrenia Research, 2019, 210, 143-148. | 2.0 | 29 |
| 79 | Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. European Journal of Clinical Pharmacology, 2019, 75, 1109-1116. | 1.9 | 8 |
| 80 | Pharmacokinetic correlates of venlafaxine: associated adverse reactions. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 851-857. | 3.2 | 5 |
| 81 | Gemfibrozil May Decrease Norclozapine Elimination. Journal of Clinical Psychopharmacology, 2019, 39, 405-407. | 1.4 | 10 |
| 82 | Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. CNS Drugs, 2019, 33, 1201-1222. | 5.9 | 19 |
| 83 | Exploring the Prevalence of Clozapine Phenotypic Poor Metabolizers in 4 Asian Samples. Journal of Clinical Psychopharmacology, 2019, 39, 644-648. | 1.4 | 39 |
| 84 | Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. International Clinical Psychopharmacology, 2019, 34, 241-246. | 1.7 | 8 |
| 85 | Clozapine Metabolism in East Asians and Caucasians. Journal of Clinical Psychopharmacology, 2019, 39, 135-144. | 1.4 | 58 |
| 86 | Studies of Half-Lives of Long-Acting Antipsychotics are Needed. Pharmacopsychiatry, 2019, 52, 45-46. | 3.3 | 5 |
| 87 | Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. Clinical Pharmacokinetics, 2019, 58, 535-543. | 3.5 | 20 |
| 88 | The clinical relevance of the pharmacological interaction between clozapine and sertraline. , 2019, 52, . | | 0 |
| 89 | TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World Journal of Biological Psychiatry, 2018, 19, 162-174. | 2.6 | 103 |
| 90 | No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment. Acta Psychiatrica Scandinavica, 2018, 138, 110-122. | 4.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Reduced clearance of venlafaxine in a combined treatment with quetiapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 116-121. | 4.8 | 18 |
| 92 | Pregnancy exposure to quetiapine – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. <i>Schizophrenia Research</i> , 2018, 195, 252-257. | 2.0 | 15 |
| 93 | Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018, 51, 9-62. | 3.3 | 787 |
| 94 | Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. <i>Clinical Pharmacokinetics</i> , 2018, 57, 729-737. | 3.5 | 14 |
| 95 | Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. <i>Journal of Affective Disorders</i> , 2018, 227, 506-511. | 4.1 | 16 |
| 96 | Pharmacokinetics of risperidone in different application forms – Comparing long-acting injectable and oral formulations. <i>European Neuropsychopharmacology</i> , 2018, 28, 130-137. | 0.7 | 22 |
| 97 | Anatomy Lessons by the Amsterdam Guild of Surgeons. <i>Medical Education and Art. Hellenike Cheirurgike Acta Chirurgica Hellenica</i> , 2018, 90, 267-273. | 0.1 | 5 |
| 98 | A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1237-1253. | 3.1 | 37 |
| 99 | Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329. | 1.7 | 12 |
| 100 | How to Treat Hypertension in Venlafaxine-Medicated Patients – Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 498-501. | 1.4 | 9 |
| 101 | Upon Rejection: Psychiatric Emergencies of Failed Asylum Seekers. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1498. | 2.6 | 11 |
| 102 | A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 625-639. | 3.1 | 34 |
| 103 | Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, <i>CYP2D6</i> and <i>ABC1</i> variants. <i>Pharmacogenomics</i> , 2018, 19, 815-823. | 1.3 | 7 |
| 104 | Psychiatric Emergencies of Asylum Seekers; Descriptive Analysis and Comparison with Immigrants of Warranted Residence. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1300. | 2.6 | 7 |
| 105 | Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, . | 2.2 | 16 |
| 106 | The effect of pharmacological interaction between a proton pump inhibitor pantoprazole and clozapine. <i>Pharmacopsychiatry</i> , 2018, 51, . | 3.3 | 0 |
| 107 | Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Journal of Affective Disorders</i> , 2017, 212, 1-6. | 4.1 | 31 |
| 108 | Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1668-1675. | 2.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 76, 101-106. | 4.8 | 7 |
| 110 | Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. <i>Schizophrenia Research</i> , 2017, 185, 51-57. | 2.0 | 21 |
| 111 | Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1059-1060. | 2.3 | 4 |
| 112 | A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 965-981. | 3.1 | 69 |
| 113 | Pregnancy exposure to citalopram – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 213-219. | 4.8 | 22 |
| 114 | Clinical response in a risperidone-medicated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 325-333. | 3.2 | 13 |
| 115 | Pharmacokinetic patterns of risperidone-associated adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1091-1098. | 1.9 | 25 |
| 116 | Risperidone-induced extrapyramidal side effects. <i>International Clinical Psychopharmacology</i> , 2016, 31, 259-264. | 1.7 | 20 |
| 117 | Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. <i>Psychoneuroendocrinology</i> , 2016, 73, 9-15. | 2.7 | 31 |
| 118 | Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 554-561. | 1.4 | 28 |
| 119 | Interaction Between Risperidone, Venlafaxine, and Metronidazole. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 730-733. | 1.4 | 7 |
| 120 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions. <i>Journal of Psychopharmacology</i> , 2016, 30, 803-809. | 4.0 | 19 |
| 121 | Keep at bay! – Abnormal personal space regulation as marker of paranoia in schizophrenia. <i>European Psychiatry</i> , 2016, 31, 1-7. | 0.2 | 32 |
| 122 | Acute Psychiatric Problems among Migrants Living in Switzerland- a Retrospective Study from a Swiss University Emergency Department. <i>Emergency Medicine: Open Access</i> , 2016, 6, . | 0.1 | 3 |